The allure of faster turnaround times suggests quicker insights and potentially fewer sequencing requirements, but these disruptive solutions often overlook a critical element: the importance of high-quality, reproducible, and confident insights.
The companies, who partnered to bring Genomenon’s Cancer Knowledgebase or “CKB” (formerly Clinical Knowledgebase) of curated variants to users of Illumina’s Connected Insights interpretation platform, say these efforts will enable scientists to interpret more oncogenic variants in more populations.
Foundation Medicine recently announced a companion diagnostic partnership with Syndax Pharmaceuticals to identify AML patients with NPM1 mutations with comprehensive genomic profiling, which, if approved, could be the first NGS CDx test to detect genomic alterations in hematologic neoplasms.
With advance planning and a diagnostics partner with demonstrated regulatory expertise, it is possible to navigate EU IVDR requirements with confidence and keep clinical trial timelines on track.
Explainable artificial intelligence, or XAI, is enabling Baylor Genetics to hasten and scale up clinical whole-genome sequencing while testing becomes more accessible and evidence for its utility grows.
Artificial intelligence models that can explicitly demonstrate their logic and expose potential biases, known as explainable AI, or XAI, are necessary for medical institutions to make healthcare decisions with increased confidence, according to Illumina.
Epigenetics is the key to unlocking the full potential of cancer therapy, including immunotherapies, by revealing deep insights into how the body reacts and responds to medication.
Foundation Medicine and Flatiron Health are introducing a novel capability for supporting companion diagnostic regulatory filings with real-world data from the Flatiron Health-Foundation Medicine Clinico-Genomic Database.
